Arcutis Biotherapeutics, Inc. ARQT
We take great care to ensure that the data presented and summarized in this overview for Arcutis Biotherapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARQT
View all-
Suvretta Capital Management, LLC New York, NY11.4MShares$156 Million7.82% of portfolio
-
Jennison Associates LLC11.4MShares$155 Million0.13% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$149 Million4.91% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$120 Million8.65% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$118 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.82MShares$92.9 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X06.71MShares$91.4 Million0.7% of portfolio
-
State Street Corp Boston, MA4.47MShares$61 Million0.0% of portfolio
-
Gilder Gagnon Howe & CO LLC New York, NY4.1MShares$55.8 Million0.91% of portfolio
-
Morgan Stanley New York, NY3.84MShares$52.3 Million0.0% of portfolio
Latest Institutional Activity in ARQT
Top Purchases
Top Sells
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Insider Transactions at ARQT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 14
2025
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
6,300
+29.61%
|
$81,900
$13.76 P/Share
|
|
May 13
2025
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
2,374
+21.49%
|
$30,862
$13.76 P/Share
|
|
May 09
2025
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
6,300
+50.0%
|
$81,900
$13.6 P/Share
|
|
May 08
2025
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
3,871
-3.24%
|
$50,323
$13.59 P/Share
|
|
May 06
2025
|
Latha Vairavan SVP Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+23.5%
|
-
|
|
May 02
2025
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
2,597
-2.13%
|
$38,955
$15.19 P/Share
|
|
May 02
2025
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
11,448
-1.24%
|
$171,720
$15.19 P/Share
|
|
May 02
2025
|
Masaru Matsuda Officer |
SELL
Open market or private sale
|
Direct |
5,030
-2.4%
|
$75,450
$15.2 P/Share
|
|
May 01
2025
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,000
-8.2%
|
$140,000
$14.64 P/Share
|
|
Apr 02
2025
|
David Joseph Topper Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,600
-4.99%
|
$144,000
$15.8 P/Share
|
|
Apr 01
2025
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,000
-7.58%
|
$150,000
$15.12 P/Share
|
|
Mar 25
2025
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
2,171
-0.23%
|
$36,907
$17.56 P/Share
|
|
Mar 24
2025
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,500
-0.16%
|
$25,500
$17.52 P/Share
|
|
Mar 17
2025
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,200
-0.13%
|
$20,400
$17.61 P/Share
|
|
Mar 14
2025
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
12,242
-9.12%
|
$183,630
$15.04 P/Share
|
|
Mar 14
2025
|
Patrick Burnett Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,242
+8.36%
|
-
|
|
Mar 13
2025
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
49,161
-15.26%
|
$737,415
$15.04 P/Share
|
|
Mar 13
2025
|
Patrick Burnett Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,008
+3.8%
|
-
|
|
Mar 04
2025
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
4,135
-0.44%
|
$53,755
$13.28 P/Share
|
|
Mar 04
2025
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
954
-0.57%
|
$12,402
$13.28 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 500K shares |
|---|---|
| Open market or private purchase | 27.8K shares |
| Exercise of conversion of derivative security | 101K shares |
| Open market or private sale | 572K shares |
|---|